Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.
Positive results of drug Validive for prevention and treatment of severe oral mucositis in patients with head and neck cancer.
Mice that produced the Smad7 protein in the oral cavity were dramatically more resistant to radiation-induced oral mucositis than were controls.
Drugs that inhibit mammalian target of rapamycin (mTOR) stopped radiation-induced damage in mice by protecting cells crucial to tissue repair.
Thermal imaging can detect early changes in the temperature of mucosal surfaces that may signal mucositis in persons with head and neck cancer who are receiving chemoradiotherapy.
Developing an evidence-based oral care policy may help to prevent or to more effectively manage oral mucositis in oncology patients.
Oral mucositis is a common side effect of both chemotherapy and radiation that patients find distressing, yet there are interventions that seem to help.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
- Immunotherapy and the Future of Prostate Cancer Treatment
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|